Scarica l'app Stockscreener
406.09
1.01%
-4.15
Dopo l'orario di chiusura:
407.50
1.41
+0.35%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$410.24
Aprire:
$410.09
Volume 24 ore:
2.76M
Relative Volume:
1.07
Capitalizzazione di mercato:
$219.55B
Reddito:
$37.30B
Utile/perdita netta:
$7.80B
Rapporto P/E:
28.24
EPS:
14.3793
Flusso di cassa netto:
$8.60B
1 W Prestazione:
+7.90%
1M Prestazione:
-7.57%
6M Prestazione:
+16.10%
1 anno Prestazione:
+41.59%
Intervallo 1D:
$404.34
$415.76
Intervallo di 1 settimana:
$376.08
$415.76
Portata 52W:
$269.77
$447.03
Amgen Inc Stock (AMGN) Company Profile
Nome
Amgen Inc
Settore
Industria
Telefono
(805)447-1000
Indirizzo
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
406.09 | 221.79B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,150.99 | 1.04T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
269.17 | 648.72B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
265.08 | 468.66B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
148.08 | 372.32B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
142.71 | 268.53B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-21 | Iniziato | Canaccord Genuity | Hold |
| 2026-03-10 | Iniziato | Jefferies | Hold |
| 2026-02-20 | Iniziato | Barclays | Equal Weight |
| 2026-01-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-12-05 | Aggiornamento | Erste Group | Hold → Buy |
| 2025-11-24 | Ripresa | Truist | Hold |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-09-03 | Ripresa | Raymond James | Mkt Perform |
| 2025-05-20 | Ripresa | Guggenheim | Neutral |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-10-14 | Downgrade | Truist | Buy → Hold |
| 2024-09-27 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-08-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2024-05-03 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | Ripresa | Raymond James | Mkt Perform |
| 2024-02-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-02 | Aggiornamento | Truist | Hold → Buy |
| 2023-10-20 | Ripresa | JP Morgan | Neutral |
| 2023-10-17 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-10-11 | Ripresa | BofA Securities | Neutral |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-04-24 | Reiterato | Oppenheimer | Outperform |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | Reiterato | Truist | Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Underperform |
| 2022-10-31 | Downgrade | Barclays | Equal Weight → Underweight |
| 2022-10-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-02-09 | Reiterato | Barclays | Equal Weight |
| 2022-02-09 | Reiterato | Jefferies | Buy |
| 2022-02-09 | Reiterato | Morgan Stanley | Equal-Weight |
| 2022-02-09 | Reiterato | Oppenheimer | Outperform |
| 2022-02-09 | Reiterato | Wells Fargo | Equal Weight |
| 2022-01-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-09-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | Iniziato | Daiwa Securities | Buy |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-10-26 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | Aggiornamento | Truist | Hold → Buy |
| 2020-10-09 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | Downgrade | Truist | Buy → Hold |
| 2020-10-08 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | Ripresa | Guggenheim | Neutral |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-03-30 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-17 | Ripresa | Morgan Stanley | Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-11-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-08-19 | Downgrade | Mizuho | Buy → Neutral |
| 2019-05-23 | Aggiornamento | Citigroup | Neutral → Buy |
Mostra tutto
Amgen Inc Borsa (AMGN) Ultime notizie
Amgen price target raised by Jefferies to $410 after positive Sjögren's data - Yahoo Finance
Amgen Stock Forecast: AMGN Reclaims $410 as Pipeline Catalysts Build - TradingKey
AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study - Yahoo Finance
Jefferies Adjusts Amgen Price Target to $410 From $367, Maintains Hold Rating - marketscreener.com
Amgen Stock Gains After Announcing Positive Phase 3 Sjögren’s Disease Trial Results - TIKR.com
Canaccord reiterates Amgen stock Hold rating on pipeline win By Investing.com - Investing.com Canada
Amgen stock rises 4.34 percent as trial data lift pipeline hopes - AD HOC NEWS
Canaccord reiterates Amgen stock Hold rating on pipeline win - Investing.com India
Oppenheimer reiterates Amgen stock rating on positive trial data - Investing.com India
Jefferies raises Amgen stock price target on drug trial success - Investing.com India
Amgen (AMGN) Following Its Sjögren's Trial Win Through A Valuation Lens - simplywall.st
Amgen touts Phase III success in systemic Sjögren's disease - The Pharma Letter
What is changing in the investment case for Amgen (NASDAQ:AMGN)? - kalkinemedia.com
Amgen Inc. (NASDAQ:AMGN) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Amgen stock heads into the open after a 4.34 percent gain - AD HOC NEWS
Is Amgen Inc (AMGN) Overvalued After 4.3% Rally? GF Value Says O - GuruFocus
Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH - The Motley Fool
Amgen stock surges on positive Sjögren’s trial results - Investing.com
Amgen stock ends the day 3.36 percent higher at USD 406.37 - AD HOC NEWS
Amgen’s Dazodalibep Outlook Is Brighter After First Phase III Readout - insights.citeline.com
Amgen, Vicor among market cap stock movers on Tuesday - Investing.com India
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
Amgen Drug Meets Goals of Key Test in Common Autoimmune Disease With No Approved Meds - MedCity News
Amgen, Vicor among market cap stock movers on Tuesday By Investing.com - Investing.com Australia
Amgen reports a Phase 3 win with Sjögren’s drug candidate - BioPharma Dive
Amgen Ranks #4 on Forbes’ Most Innovative Large Companies List - Amgen
AMGN Jumps After Win In Sjögren’s Disease Trial As Citi Flags ‘Open Questions’ - Stocktwits
Amgen Hits Primary Endpoint In Sjögren's Trial, But Approval Filing Awaits Another Trial Data - Benzinga
State Street Corp Increases Position in Amgen Inc. $AMGN - MarketBeat
Amgen's autoimmune drug succeeds in late-stage trial - Reuters
Amgen (AMGN) Posted Positive Phase 3 Results In Sjögren's Disease - Yahoo Finance
Why Amgen (AMGN) Stock Is Up Today - Quiver Quantitative
Ionis, Otsuka's Phase 3 win in ALS subtype; Boehringer's up to $1B cancer deal - Endpoints News
Amgen Inc Stock (AMGN) Moved Up by 3.90% on Sep 22: Facts Behind the Movement - TradingKey
Amgen Drug May Offer Sjögren’s Patients First Effective Therapy - bloomberg.com
Why is Amgen stock surging today? - Investing.com
Amgen posts trial win for Sjögren's disease drug (AMGN:NASDAQ) - Seeking Alpha
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE - Amgen
Amgen stock gains 1.95 percent as estimates face pressure - AD HOC NEWS
Erste Group Bank Brokers Reduce Earnings Estimates for Amgen - MarketBeat
Malay Naik Appointed Executive Director, US Brand Lead – Oncology at Amgen - hrtoday.in
Amgen stock heads into the open after a 1.95 percent gain - AD HOC NEWS
Amgen Inc Lobbyists, 2006 - OpenSecrets
Morgan Stanley flags Amgen’s edge after heart-drug rival stumbles - thestreet.com
Amgen stock ends the day 1.95 percent higher at the close - AD HOC NEWS
Veeva Expands Amgen Partnership With Global Vault CRM Rollout Plan - Yahoo Finance
The Zacks Analyst Blog Highlights AMD, Linde, Amgen and INNOVATE - Yahoo Finance
Amgen Inc Agencies, 2026 - OpenSecrets
Amgen Inc. (AMGN) Stock Analysis: Navigating Growth with a Robust Pipeline and a 2.61% Dividend Yield - DirectorsTalk Interviews
Amgen stock heads into the open after a weaker close - AD HOC NEWS
Amgen stock gains as FDA approval and price targets land - AD HOC NEWS
Amgen Inc Azioni (AMGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Amgen Inc Azioni (AMGN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Khosla Rachna | SVP, Business Development |
Aug 11 '26 |
Sale |
412.57 |
2,000 |
825,134 |
6,404 |
| Khosla Rachna | SVP, Business Development |
Aug 13 '26 |
Sale |
416.43 |
1,252 |
521,365 |
6,404 |
0.83%
1.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):